Filament Health, developer of clinical-stage natural psychedelics FLHLF and the Copenhagen Psychiatric Center’s joint clinical trial has been approved by the Danish Medicines Agency and is scheduled to start in February this year.

The study, led by Prof. Anders Fink-Jensen and Ph.D. Candidate Mathias Ebbesen Jensen, will evaluate Filament’s natural psilocybin drug candidate for the treatment of Alcohol Use Disorders (AUD).

Filament’s co-founder and CEO Benjamin Lightburn is thrilled. “The Psychiatric Center Copenhagen is an internationally recognized psychiatric research facility. We are proud that Mathias Ebbesen Jensen and Professor Fink-Jensen have selected Filament’s drug candidate for a clinical trial of this caliber, and we look forward to supporting their important research.”

See also: EXCLUSIVE: The psychedelics debate ‘rages’ as Filament introduces the ayahuasca pill

The PI of the study, Prof. Anders Fink-Jensen, agreed. “Alcohol use disorders are a widespread global public health problem and represent a major risk factor for disability and mortality. Clinical data suggest that psilocybin has potential as a treatment for AUD, and we intend to extend these findings with this study extend.”

Using the Good Manufacturing Process (GMP) drug candidate originating from Filament’s Metro Vancouver laboratory, the study aims to determine the effects of a single dose of 25 milligrams of psilocybin on an alcohol abuse-affected brain.

The study is the third European study of its kind to be approved to test the company’s natural psilocybin.

Photo: Benzinga edit with photo by Cannabis_Pic and Gorodenkoff and Troyan on Shutterstock.